Long-term, Substantial Weight Loss and Insulin Regulation of Lipolysis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-01

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is not known how much improvement in insulin regulated lipolysis (the breakdown of triglycerides) occurs following substantial, sustained weight loss. Researchers will test the effects of inflammation and lipolysis regulation in people before and after bariatric surgery (sleeve gastrectomy) to answer these questions.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus

NCT01882036

Type 2 Diabetes Mellitus Insulin Resistance

COMPLETED NA

Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery

NCT01007955

Morbid Obesity Insulin Resistance Non-Alcoholic Fatty Liver Disease

COMPLETED

Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome

NCT05408728

Obese Healthy Bariatric Surgery Candidate

ENROLLING_BY_INVITATION

Adjustable Gastric Banding and Its Effects on Postprandial Glucose Metabolism Independent of Weight Loss

NCT01094054

Obesity Diabetes

COMPLETED PHASE4

Improvement of Insulin Resistance After Bariatric Surgery

NCT03853590

Obesity Bariatric Surgery Candidate Insulin Tolerance

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to determine whether the adipose inflammatory cell and cytokine content in Class III obesity is related to lipolysis insulin resistance and, if so, whether sustained, substantial weight loss one year following bariatric surgery reduces inflammation in parallel with improved insulin regulation of lipolysis

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity, Morbid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Study insulin action and adipose function before and after weight loss from gastric sleeve surgery

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gastric sleeve surgery

before and after weight loss from bariatric surgery

Group Type EXPERIMENTAL

Gastric sleeve/bariatric surgery

Intervention Type PROCEDURE

weight loss

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gastric sleeve/bariatric surgery

weight loss

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI 40 - 50 kg/m2.
* Mo active physical illness that would interfere with mobility or weight loss after bariatric surgery

Exclusion Criteria

* Type 1 or Type 2 Diabetes diagnosis or fasting plasma glucose ≥126 mg/dL
* Active coronary artery disease
* Participation in structured exercise (\>2 times per week for 30 minutes or longer)
* Smoking
* Medications known to affect adipose tissue metabolism (e.g., beta blockers, corticosteroids)
* Renal insufficiency (serum creatinine \> 1.5mg/dl)
* Chronic active liver disease (Bilirubin \> 17mmol/L, AST \> 144 IU/L, or ALT\>165IU/L)
* Pregnancy or breastfeeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No